GE HealthCare
GEHC
$62.83
-0.38%
GE HealthCare Technologies is a leading medical technology firm specializing in imaging, ultrasound, advanced visualization solutions, patient care, and pharmaceutical diagnostics. As a market leader in imaging and ultrasound equipment, it holds a distinct competitive position with approximately half of its revenue recurring from servicing, pharmaceutical diagnostics, and digital solutions. The current investor narrative centers on margin pressures from cost inflation and a lowered 2026 earnings guidance, which has weighed on sentiment despite the company's strong market position and diversified geographic footprint.…
GEHC
GE HealthCare
$62.83
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating: Hold. The thesis is that GEHC offers a compelling forward valuation and strong cash flow, but near-term margin headwinds and technical weakness warrant caution. The analyst consensus is Buy with an average target of $79.44, implying 26% upside, but the stock is in a downtrend and faces fundamental challenges.
Supporting evidence: Forward P/E of 11.76x is a 47% discount to the healthcare sector average of ~22x. Revenue growth accelerated to 7.41% YoY in Q1 2026. Free cash flow TTM of $1.52B provides a 4.1% yield. ROE of 20.08% is strong. However, net margin compression from 11.81% to 7.58% YoY and lowered 2026 guidance are significant concerns. The stock's 1-year decline of 17.27% and proximity to the 52-week low of $58.75 indicate persistent selling pressure.
Risks & Conditions: The biggest risks are margin compression from cost inflation, potential further guidance cuts, and the stock's technical downtrend. This Hold would upgrade to Buy if net margins stabilize above 10% and the stock holds above $60 support. It would downgrade to Sell if revenue growth decelerates below 5% or margins fall below 7%. Valuation verdict: The stock appears undervalued relative to its history and peers on a forward P/E basis, but the discount is warranted by near-term earnings uncertainty. For patient investors with a 12-month horizon, the risk/reward is balanced.
Sign up to view all
GEHC 12-Month Price Forecast
The forward-looking view is neutral with a slight bullish tilt on valuation. Revenue growth is reaccelerating, and the forward P/E of 11.76x is deeply discounted, providing a margin of safety. However, margin compression from cost inflation and lowered guidance are significant near-term headwinds. The stock's technical downtrend and proximity to the 52-week low add caution. If margins stabilize and the company delivers on revenue growth, the stock could re-rate higher. If margins continue to deteriorate, further downside is possible. The stance would upgrade to bullish if net margins show sequential improvement above 9% and the stock breaks above $70 resistance. It would downgrade to bearish if revenue growth falls below 5% or margins drop below 7%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $79.33 and implied upside of +26.3% versus the current price.
Average Target
$79.33
0 analysts
Implied Upside
+26.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $98
Analyst target range
The stock is covered by 18 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.74 (1=Strong Buy, 5=Sell). The average target price is $79.44, implying approximately 26% upside from the current price of $63.07. The consensus leans bullish, with a majority of analysts recommending Buy or Overweight. The target price range spans from a low of $65.00 to a high of $98.00. The high target of $98.00 assumes a significant recovery in margins and growth, potentially driven by new product cycles or cost improvements. The low target of $65.00 is only slightly above the current price, suggesting downside risk is limited but that some analysts see minimal upside. Recent ratings actions include a downgrade from Goldman Sachs (Buy to Neutral) and an upgrade from UBS (Sell to Neutral), indicating mixed sentiment. The wide spread between low and high targets ($33) signals high uncertainty about the company's near-term performance, but the average target still offers substantial upside.
Bulls vs Bears: GEHC Investment Factors
GEHC presents a classic value-versus-momentum tension. On the bull side, revenue growth is reaccelerating, the forward P/E of 11.76x is deeply discounted versus the sector, and free cash flow remains robust. The analyst consensus is Buy with 26% average upside. On the bear side, margin compression from $250M in cost inflation and lowered 2026 guidance have triggered a sustained downtrend, with the stock down 17% over one year and near its 52-week low. The single most important tension is whether the margin pressure is transitory or structural. If cost inflation eases and margins recover, the low forward P/E could drive significant upside. If margins continue to compress, the stock could test the 52-week low of $58.75 or below. Currently, the bear case has stronger near-term evidence given the guidance cut and technical weakness, but the valuation and cash flow provide a compelling long-term entry for patient investors.
Bullish
- Revenue Growth Reaccelerating: Q1 2026 revenue grew 7.41% YoY to $5.131B, accelerating from 4.67% in Q4 2025. This positive momentum suggests the company is gaining traction despite macro headwinds.
- Attractive Forward Valuation: Forward P/E of 11.76x is a 47% discount to the healthcare sector average of ~22x. This low multiple provides a margin of safety if earnings recover.
- Strong Free Cash Flow Generation: TTM free cash flow of $1.52B yields ~4.1% at current market cap. This cash generation supports debt service, R&D, and potential shareholder returns.
- High ROE and Profitability: ROE of 20.08% indicates efficient capital use. Despite margin compression, the company remains profitable with net income of $389M in Q1 2026.
Bearish
- Margin Compression from Cost Inflation: Net margin fell from 11.81% in Q1 2025 to 7.58% in Q1 2026 due to $250M in cost inflation. Operating margin dropped from 13.17% to 10.04% YoY.
- Lowered 2026 Earnings Guidance: The company reduced its 2026 EPS outlook, citing persistent cost pressures. This triggered a sharp stock decline and analyst downgrades, including Goldman Sachs moving to Neutral.
- Sustained Downtrend and Weak Momentum: Stock is down 17.27% over 1 year and trades near its 52-week low of $58.75. The 3-month relative strength vs SPY is -20.19%, indicating persistent underperformance.
- High Uncertainty in Analyst Targets: The spread between low ($65) and high ($98) analyst targets is $33, signaling significant disagreement. The low target is only 3% above current price, limiting upside conviction.
GEHC Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -17.27% and a 52-week range of $58.75 to $89.77. Currently trading at $63.07, the stock sits at approximately 70% of its 52-week range, near the lows, suggesting a value opportunity but also reflecting persistent selling pressure. The price is well below its 52-week high, indicating a lack of momentum and potential oversold conditions. Over the past 1 month, the stock has gained 3.14%, while the 3-month change is -15.52%, showing a short-term bounce within a longer-term decline. This divergence suggests a potential mean-reversion attempt, but the 1-year downtrend remains intact. The 1-month relative strength vs. SPY is +2.83%, indicating slight outperformance recently, but the 3-month relative strength is -20.19%, confirming the broader weakness. The stock's beta of 0.839 implies it is less volatile than the market, which may limit downside but also reduce upside participation in rallies. Key support is at the 52-week low of $58.75, a break below which could signal further downside. Resistance is at the 52-week high of $89.77, and a breakout above that level would indicate a trend reversal. The current price is near support, and a breakdown could accelerate selling, while a bounce from here may find resistance around $70.
Beta
0.84
0.84x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-17.3%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | +2.0% | -0.6% |
| 3m | -13.1% | +5.4% |
| 6m | -22.5% | +8.3% |
| 1y | -17.3% | +18.3% |
| ytd | -24.1% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
Revenue in Q1 2026 was $5.131 billion, up 7.41% year-over-year, accelerating from the 4.67% growth in Q4 2025. The Imaging segment contributed $2.299 billion, PCS $704 million, and PDx $770 million, with Imaging being the primary growth driver. The revenue trajectory is positive, with growth reaccelerating after a deceleration in late 2025, supporting the investment case for a recovery. Net income in Q1 2026 was $389 million, with a net margin of 7.58%, down from 11.81% in Q1 2025 due to cost inflation. Gross margin was 38.53%, relatively stable compared to 39.65% in Q2 2025, but operating margin compressed to 10.04% from 13.17% a year ago. The company remains profitable, but margin compression is a key concern, though the trajectory shows sequential improvement from Q4 2025's 3.94% net margin. The balance sheet shows a debt-to-equity ratio of 0.96, manageable leverage, and a current ratio of 1.18, indicating adequate liquidity. Free cash flow (TTM) is $1.52 billion, providing a solid cash generation capability. ROE is 20.08%, reflecting strong returns on equity, while the free cash flow yield is approximately 4.1%, suggesting reasonable valuation relative to cash flow.
Quarterly Revenue
$5.1B
2026-03
Revenue YoY Growth
+7.4%
YoY Comparison
Gross Margin
38.5%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 17.99x, while the forward P/E is 11.76x, implying the market expects earnings growth. The gap between trailing and forward P/E suggests that earnings are expected to increase, which aligns with the revenue growth trajectory. Compared to the healthcare sector average P/E of approximately 22x, GEHC's trailing P/E of 17.99x represents a discount of about 18%. This discount may be justified by the recent margin compression and lowered guidance, but the forward P/E of 11.76x is even more attractive if earnings recover. Historically, the stock's P/E has ranged from about 12x to 50x over the past few years. The current trailing P/E of 17.99x is near the lower end of its historical range, suggesting the stock is relatively cheap compared to its own history. This could indicate a value opportunity if fundamentals improve, but it also reflects the market's skepticism about near-term earnings.
PE
18.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is margin compression from cost inflation. Net margin dropped from 11.81% in Q1 2025 to 7.58% in Q1 2026, a 36% decline. Operating margin fell from 13.17% to 10.04% over the same period. The company cited $250 million in cost inflation that is difficult to offset due to long sales cycles. Debt-to-equity of 0.96 is manageable but limits financial flexibility. Free cash flow of $1.52B TTM provides a cushion, but if margins continue to erode, cash generation could weaken. Revenue concentration in Imaging (45% of revenue) exposes the company to cyclical hospital capital spending. A slowdown in hospital budgets could pressure top-line growth.
Market & Competitive Risks: The stock trades at a trailing P/E of 17.99x, which is a discount to the sector average of 22x, but this discount may be justified by margin headwinds. With a beta of 0.839, the stock is less volatile than the market, but it has underperformed the S&P 500 by 35.6% over the past year. Competitive risks include RadNet's $270M AI acquisition, which could pressure GEHC's advanced visualization segment. Regulatory headwinds in China (11% of revenue) could add uncertainty. The wide analyst target spread ($65-$98) reflects high uncertainty, and a downgrade from Goldman Sachs signals waning institutional confidence.
Worst-Case Scenario: If cost inflation persists and margins continue to compress, earnings could fall further, triggering additional analyst downgrades and selling. The stock could break below the 52-week low of $58.75, potentially testing the next support level around $55. From the current price of $63.07, a decline to $58.75 represents a loss of approximately 6.9%, but if the downtrend accelerates, losses could reach 12-15% or more. The historical max drawdown of -32.53% suggests that in a severe scenario, the stock could fall to around $42.50, implying a potential loss of 32.6% from current levels.
FAQ
The key risks are: 1) Margin compression from cost inflation – net margin fell from 11.81% to 7.58% YoY, and the company cited $250M in cost pressures that are difficult to offset. 2) Further guidance cuts – the lowered 2026 EPS outlook triggered a sharp stock decline and analyst downgrades. 3) Technical downtrend – the stock is down 17% over one year and near its 52-week low, with weak relative strength. 4) Competitive pressure – RadNet's $270M AI acquisition could challenge GEHC's advanced visualization segment. 5) Macro sensitivity – hospital capital spending cycles and China regulatory risks (11% of revenue) could impact growth. The most severe risk is persistent margin erosion leading to further earnings disappointment and a break below $58.75 support.
The 12-month forecast is mixed. The base case (50% probability) expects margins to stabilize and revenue to grow 5-7%, with the stock reaching the average analyst target of $79.44, implying 26% upside. The bull case (25% probability) sees margin recovery and a re-rating to $75-$98, driven by easing cost inflation and strong execution. The bear case (25% probability) anticipates further margin compression and guidance cuts, with the stock falling to $55-$65, testing the 52-week low of $58.75. The most likely scenario is the base case, assuming cost inflation moderates and the company delivers on its revenue guidance. Key assumptions include stable gross margins above 38% and net margins recovering to 8-9%.
GEHC appears undervalued relative to its history and peers. The trailing P/E of 17.99x is below the healthcare sector average of ~22x, and the forward P/E of 11.76x is even more attractive, implying the market expects earnings growth. Historically, the stock's P/E has ranged from 12x to 50x, so the current level is near the lower end. The price-to-sales ratio of 1.82x and EV/EBITDA of 11.34x are also reasonable. However, the low valuation is justified by near-term margin compression and lowered guidance. The market is pricing in pessimism about earnings recovery. If margins improve, the stock could re-rate significantly. If margins worsen, the valuation could contract further. Overall, the stock is undervalued on a forward basis but fairly valued considering the risks.
GEHC presents a mixed risk/reward. On the positive side, the forward P/E of 11.76x is a 47% discount to the healthcare sector average of ~22x, and the analyst consensus is Buy with an average target of $79.44, implying 26% upside. The company generates strong free cash flow of $1.52B TTM and has a high ROE of 20.08%. However, near-term margin compression from $250M in cost inflation and lowered 2026 guidance have driven the stock down 17% over the past year. The stock is near its 52-week low of $58.75, suggesting limited downside but also reflecting persistent selling pressure. For long-term investors with a 12-month horizon, it could be a good buy if margins stabilize. For short-term traders, the downtrend and weak momentum make it risky. A prudent approach is to wait for confirmation of margin improvement before initiating a position.
GEHC is better suited for long-term investment given its defensive healthcare profile, strong cash flow, and attractive valuation. The stock's beta of 0.839 indicates lower volatility than the market, making it a portfolio stabilizer. However, the near-term margin headwinds and technical downtrend make it less suitable for short-term trading. The dividend yield is minimal at 0.17%, so income investors may look elsewhere. For long-term investors, a minimum holding period of 12-18 months is recommended to allow for margin recovery and earnings growth. Short-term traders should wait for a confirmed breakout above $70 resistance or a clear catalyst before entering. The stock's earnings visibility is moderate, with recurring revenue (~50%) providing some stability.